Ocaliva®

Product Details

Ocaliva® is indicated for the treatment of primary biliary cholangitis (also known to as primary biliary cirrhosis) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.

Intercept Pharma International Ltd. is the MA-Holder and AOP Health has the distribution right